Pantop%252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a substituted benzimidazole proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is available as oral delayed-release tablets, granules for oral suspension, and intravenous (IV) injection. ## Primary Indications * Erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. * Short-term treatment of GERD (off-label/guideline use). ## Adult Dosing * **Erosive Esophagitis:** 40 mg PO/IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg PO once daily. * **Pathological Hypersecretory Conditions:** 40 mg PO twice daily; dosages up to 240 mg/day have been utilized; titration based on clinical response. * **IV Administration:** Administer IV doses via rapid injection (2 minutes) or short infusion (15 minutes). ## Pediatric Dosing * **GERD/Erosive Esophagitis (≥5 years):** * 15 kg to <40 kg: 20 mg once daily. * ≥40 kg: 40 mg once daily. * Maximum duration: 8 weeks. * **Neonates/Infants (<5 years):** Safety and efficacy not established for GERD; use is generally off-label and requires institutional protocol consultation. ## Dose Adjustments * **Renal Impairment:** No dose adjustment necessary. * **Hepatic Impairment:** Use with caution; monitor liver function. Consider lower doses or less frequent administration in severe impairment. ## Contraindications * Hypersensitivity to pantoprazole or any component of the formulation. * Concomitant use with rilpivirine-containing products (due to decreased rilpivirine absorption). ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (long-term/high-dose). ## Key Drug Interactions * **pH-Dependent Drugs:** PPIs decrease the absorption of drugs requiring acidic environments (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil). * **CYP2C19 Inhibitors/Inducers:** May affect pantoprazole systemic exposure (though pantoprazole is generally considered to have fewer DDI risks than omeprazole). * **Methotrexate:** Potential increase in methotrexate levels when used concurrently; consider holding PPI therapy during methotrexate administration. ## Monitoring * **Baseline/Intermittent:** Magnesium levels (if long-term therapy is planned), Vitamin B12 (if long-term therapy is planned). * **Clinical:** Monitor for signs of *C. difficile* (persistent/watery stools), bone density (in high-risk patients), and renal function. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. Granules for oral suspension can be mixed with applesauce or juice and administered via nasogastric tube. * **Tapering:** Long-term users may experience rebound hypersecretion upon discontinuation; consider a gradual taper for patients on long-term daily therapy. * **"As Needed" Use:** PPIs are most effective when taken daily; "as needed" (PRN) dosing is generally ineffective for GERD management. *** *Disclaimer: This information is for educational purposes only. Clinical practice guidelines vary by institution and region. Always verify specific dosing, safety, and contraindications via current local protocols, clinical pharmacist consultation, or official institutional resources before prescribing.*